News
Tharimmune, Inc. (the “Company” and “Tharimmune”) (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback